Zimmer Biomet recently announced that the FDA has cleared its ROSA Shoulder, marking a significant milestone.
The clearance makes the orthopaedics company the first to market with robotic-assisted shoulder replacement surgery.
ROSA Shoulder is the world’s premier robotic surgery system tailored specifically for shoulder replacement procedures.
The system represents the fourth application within the ROSA Robotics portfolio, following the successful deployment of the ROSA Knee System for total knee arthroplasty and the ROSA Hip System for total hip replacement surgeries.
Ivan Tornos, Zimmer Biomet’s president and CEO, expressed pride and excitement at being the pioneering company to introduce a robotic surgical assistant dedicated to both anatomic and reverse shoulder replacement surgeries.
He emphasised ROSA Shoulder’s potential to empower surgeons with enhanced precision and efficiency through integrating robotics and data analytics.
According to the manufacturers, ROSA Shoulder’s innovative design offers surgeons ‘unparalleled flexibility, enabling the execution of total shoulder replacement procedures using either anatomic or reverse techniques’.
Its advanced capabilities facilitate precise implant placement, contributing to improved patient outcomes.
It also eliminates the need for a central pin in the glenoid during procedures, streamlining the insertion of instruments and reducing complexity.
ROSA Shoulder leverages patient-specific data to inform surgical decision-making. Pre-operatively, the system seamlessly integrates with the Signature ONE Surgical Planning System 2.0, facilitating comprehensive visualisation, planning and guide creation based on 3-D imaging.
It provides real-time intra-operative data during surgery, empowering surgeons to execute personalised glenoid and humeral placement plans with unprecedented control and validation.
The ultimate goal is to minimise complications and enhance patient safety and satisfaction.
Dr John W Sperling, a professor of orthopaedic surgery at Mayo Clinic, commended ROSA Shoulder’s potential to address the challenges associated with accurate glenoid and humeral placement, critical factors for successful post-operative function and implant longevity.
He highlighted the system’s ability to simulate procedures beforehand and provide live feedback during surgery, revolutionising the approach to shoulder replacement surgery.
ROSA Shoulder is set to be commercially available in the US in the latter half of 2024, further bolstering Zimmer Biomet's ZBEdge Dynamic Intelligence portfolio.
It will integrate with the mymobility Digital Care Management Platform, offering comprehensive support to patients undergoing shoulder replacement procedures.
Photo caption - The ROSA Shoulder System for robot-assisted surgery. Photo: Zimmer Biomet.
